Pfizer’s Cardura
Executive Summary
Is "approvable." FDA issued a letter to the company Aug. 8, stating that Cardura (doxazosin) could be approved as a once-daily treatment for hypertension. The NDA for Cardura was filed in March 1987. Cardura received FDA's Cardio-Renal Drugs Advisory Committee's recommendation for approval in May 1989. The committee determined that doxazosin was comparable to other antihypertensives such as atenolol, nadolol and metoprolol when patients were in a standing position. They found that the drug was somewhat less effective in patients in the supine position ("The Pink Sheet" May 8, 1989, p. 6). Cardura will be marketed by Pfizer's Roerig division.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.